Activity Overview
Multiple sclerosis (MS) is a chronic, immune-mediated disease of the central nervous system (CNS) in which disability progression is increasingly attributed to chronic, compartmentalized neuroinflammation behind the blood-brain barrier. Bruton tyrosine kinase (BTK) has emerged as a therapeutic target of interest due to its central role in signaling processes in B cells and myeloid cells of the CNS. Several BTK inhibitors, which remain under investigation for MS, are designed to modulate these processes on both sides of the blood-brain barrier to varying degrees. This CME-certified activity features 2 expert faculty who pair expert commentary with video animations to illustrate the pathophysiology of neuroinflammation in MS, the mechanisms of action of BTK inhibition, and the emerging clinical trial data for this investigational class.
Target Audience
This educational activity is directed toward neurologists, neuromuscular specialists, neuroimmunologists, nurse practitioners, physician associates, and other health care providers involved in the diagnosis and management of MS.
Learning Objectives
Upon successful completion of this activity, you should be better prepared to:
- Identify the role of BTK in the pathophysiological processes underlying neuroinflammation in MS
- Analyze clinical trial data for BTK inhibitors for MS
Stephen Krieger, MD, FAAN
Professor of Neurology
Icahn School of Medicine at Mount Sinai
New York, NY
Disclosures: Advisor, Consultant, Fee for Service Recipient: EMD Serono, Genentech, Invivyd, MedRX, PTC Therpaeutics, Sandoz, TG Therapeutics, Zenas Speakers/Bureau: Genentech, TG Therapeutics Grant/Research Funding: Biogen, BMS, Novartis, Sanofi
Enrique Alvarez, MD, PhD
Professor of Neurology
Vice Chair of Clinical Research, Department of Neurology
University of Colorado School of Medicine
Rocky Mountain Multiple Sclerosis Center
Aurora, CO
Disclosures: Advisor, Consultant, Fee for Service Recipient: Biogen, BMS, EMD Serono/Merck, Genentech/Roche, Horizon/Amgen, Novartis, Sanofi, Cionic, Tg Therapeutics. Grant/Research Funding: Biogen, BMS, Genentech/Roche, Novartis, Sanofi, TG Therapeutics, Patient-Centered Outcomes Research Initiative, National Multiple Sclerosis Society, National Institutes of Health, Rocky Mountain MS Center
The staff of Physicians’ Education Resource®, LLC, have no relevant financial relationships with ineligible companies.
PER® mitigated all conflicts of interest for faculty, staff, and planners prior to the start of this activity by using a multistep process.
Off-Label Disclosure and Disclaimer
This accredited continuing education activity was planned in accordance with the ACCME Standards for Integrity and Independence to ensure balance, objectivity, independence, and scientific rigor. Faculty were instructed to use generic names when possible and to base recommendations on the best available evidence. Proprietary product names may be referenced in clinical discussion for educational purposes only and do not imply endorsement.
This activity may include discussion of investigational, unapproved, or off‑label uses of drugs or devices. Learners are advised to consult prescribing information for products discussed. Content is provided for educational purposes only and is not a substitute for the independent clinical judgment of a health care professional. Learners are encouraged to critically evaluate the information presented and apply their own clinical judgment.
The views expressed are those of the individual faculty members and do not necessarily reflect the views of the accredited provider or any entity providing commercial support.
This activity may have used artificial intelligence-assisted tools to support educational development. All content was reviewed and approved by qualified faculty or planners. The accredited provider retains full responsibility for accuracy, balance, and independence.